The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
Publication|Articles|December 30, 2024
Peers & Perspectives in Oncology
- December II, 2024
- Pages: 76
Roundtable Roundup: Relapsed CLL After 2 Prior Lines
Author(s)Targeted Oncology Staff
Fact checked by: Dylann Bailey
In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).
Advertisement
- CASE SUMMARY
- A 65-year-old man who was diagnosed with CLL in 2019 presented to his oncologist at routine follow-up.
- Medical history: type 2 diabetes controlled with insulin
- Patient received previous treatments with:
- First line: acalabrutinib (Calquence) monotherapy
- Achieved good clinical response over 3 years but later progressed on therapy
- Second line: venetoclax (Venclexta) plus rituximab (Rituxan)
- Completed 24-month treatment regimen
- Was in treatment-free interval for 6 months
- Due to disease progression, his hemoglobin has dropped over the past 3 months and is currently at 10 g/dL.
- At follow-up, the patient is now aged 70 years and does not report any symptoms yet.
- ECOG performance status: 0
Articles in this issue
almost 2 years ago
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPCalmost 2 years ago
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseasesalmost 2 years ago
Managing Intermediate-Risk Myelofibrosis With RuxolitinibNewsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.
Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering a scalable model for at-home care.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
During a live event, Seth M. Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durability of PFS and OS Benefit vs. Historical Control
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
Opamtistomig Earns FDA Fast Track in First-Line Biliary Tract Cancer
4
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
5